Sarcoma Treatment in 2026: From Gerald Ford’s Drugs to Trabectedin and Pembrolizumab

Introduction: A Field Long Defined by What Doesn’t Work

Sarcomas are among the most challenging malignancies in oncology; not because they are uniformly aggressive, but because they encompass more than 170 histologically and biologically distinct entities, each with its own behavior, its own vulnerabilities, and its own resistance mechanisms. For decades, therapeutic progress was frustratingly slow. Doxorubicin and dacarbazine, two drugs approved when Gerald Ford was president of the United States, have remained key components of systemic therapy for sarcomas ever since.

That is beginning to change. The pace of drug approvals has accelerated, and the field is moving, cautiously, away from one-size-fits-all cytotoxic therapy toward biologically informed treatment. Two recent developments stand out: a phase 3 trial in metastatic leiomyosarcoma that produced an overall survival benefit (a rare and meaningful achievement in this field), and a randomized trial establishing neoadjuvant pembrolizumab combined with radiation therapy as having a disease-free survival benefit in specific soft tissue sarcoma histologies.

Understanding Sarcomas: Grade Above All Else

Unlike most solid tumor types, sarcoma staging incorporates tumor grade as a central prognostic variable, not just tumor size and nodal or metastatic status. Grade is likely the single most important determinant of prognosis and should anchor every clinical discussion with sarcoma patients. Low-grade lesions, even if large, generally carry a favorable prognosis. High-grade tumors, even if relatively small, are more aggressive and associated with meaningfully worse outcomes at every stage.

Soft tissue sarcoma staging systems are increasingly complex. They reflect both anatomic and subtype-specific considerations, reflecting better biological understanding across histologies. Bone sarcoma staging systems remain relatively simple but are expected to evolve.

Primary Treatment: Surgery Remains the Cornerstone

Surgery is the oldest and still one of the most effective treatments across all cancer types, and that holds especially true in sarcoma. Combined surgery and radiation therapy achieves local control in approximately 90% of cases, a remarkably effective rate by any standard in oncology.

The persistent challenge is distant disease. In approximately half of patients with high-grade sarcomas, metastatic disease develops despite excellent local control. Improving systemic therapy to address this remains a central unmet need.

Perioperative Chemotherapy: Who Actually Benefits

The role of perioperative chemotherapy in sarcoma is nuanced and histology-dependent.

Proven benefit (level 1 evidence): For Ewing’s sarcoma, osteosarcoma, and rhabdomyosarcoma, chemotherapy is an integral part of treatment and dramatically improves survival. In osteosarcoma, surgery alone produces a 5 to 10% cure rate. Combined with perioperative chemotherapy, that rises to 60 to 65%. These are patients who must receive systemic therapy.

Contested benefit (soft tissue sarcomas): For other soft tissue sarcomas, the picture is less clear. Multiple randomized trials and meta-analyses have shown a trend toward overall survival benefit with adjuvant chemotherapy (doxorubicin plus ifosfamide), but none has reached statistical significance for OS as a primary endpoint. The board exam answer is no adjuvant chemotherapy for soft tissue sarcomas outside the proven histologies, but real-world practice is more nuanced.

A post hoc analysis from one of the better-conducted and recent adjuvant trials is clinically instructive. Using the Sarculator nomogram (freely available as a phone app), patients with soft tissue sarcomas can be stratified by estimated 10-year overall survival. Among patients with predicted survival greater than 60%, adjuvant chemotherapy made no difference. Among those with predicted survival of 60% or less (the highest-risk group), chemotherapy improved overall survival. This post hoc analysis has not been confirmed in a prospective randomized trial and likely will not be. It is, however, a reasonable approach to use in identifying those soft tissue sarcoma patients most likely to benefit from perioperative chemotherapy. Incorporating prognostic estimates from the Sarculator and other nomograms into clinical practice can allow providers and patients to have a more informed discussion about the use of peri-operative therapy in primary soft tissue sarcoma treatment.

Neoadjuvant Pembrolizumab: A New Addition for Select Histologies

A meaningful recent advance in the perioperative setting is neoadjuvant pembrolizumab for specific soft tissue sarcoma subtypes: undifferentiated pleomorphic sarcoma (UPS), dedifferentiated liposarcoma, pleomorphic liposarcoma, and myxofibrosarcoma (which shares biological features with UPS). The majority of the patients enrolled however were UPS.

The SARC032 trial enrolled approximately 130 patients, primarily with extremity tumors, and administered pembrolizumab concurrently with neoadjuvant radiation therapy prior to surgery, followed by pembrolizumab continuation to one year, versus radiation and surgery alone. The primary endpoint was disease-free survival, and the trial met this endpoint.

Sub-analyses showed no difference in local recurrence rates between arms, but a non-statistically-significant trend toward reduced distant recurrence with pembrolizumab, consistent with the hypothesis that immunotherapy’s benefit in sarcoma, when it exists, is primarily in controlling micrometastatic disease rather than local tumor biology. No benefit in overall survival was documented, although the study was not powered to detect such a benefit.

This regimen is now recognized in NCCN guidelines for these histologies. For patients unable to tolerate chemotherapy, neoadjuvant pembrolizumab concurrent with radiation represents a viable alternative. Open questions remain: efficacy at non-extremity sites (including retroperitoneal tumors), applicability to other histologies, and the survival signal that would require a larger, more powerful trial to detect.

Pembrolizumab in Advanced Sarcoma: SARC028

The SARC028 trial, a single-arm study of pembrolizumab across multiple sarcoma histologies, remains an important reference even years after its initial publication. The response rates by histology were strikingly varied. UPS showed deep and durable responses, represented by the red waterfall bars in the original publication; the results from that cohort continue to support pembrolizumab’s use in UPS in the advanced setting. This is a histology-specific finding, not a class effect across all sarcomas.

PD-1-targeted therapy has also found use in other settings in sarcoma treatment. These include cutaneous angiosarcoma and alveolar soft part sarcoma. Further investigation of the role of immunotherapies in sarcoma management remains an area of active investigation.

Doxorubicin: Still Essential, and Its Cardiotoxicity Is Addressable

Doxorubicin remains the most important single agent in sarcoma systemic therapy. Median overall survival in the control arm of a 1999 meta-analysis was 51 weeks; in a 2014 randomized trial, also 51 weeks. Its principal limitation is dose-dependent cardiomyopathy, which has historically constrained its use.

Dexrazoxane (Zinecard), an iron chelator, is FDA-approved for cardioprotection when patients have received 300 mg/m² of doxorubicin. Historically initiated at that threshold (approximately cycle 5 or 6), data from a clinical trial designed for another purpose showed that early incorporation of dexrazoxane from cycle 1 suppresses cardiomyopathy development and, in doxorubicin-sensitive patients, may allow dramatically higher cumulative doses to be administered safely. Our current practice at City of Hope has largely adopted dexrazoxane from cycle 1 for patients expected to receive significant doxorubicin exposure.

Randomized clinical trials in the 1980s–1990s supported continuous infusion of doxorubicin as a means to reduce cardiomyopathy risk. This has not been adopted widely in sarcoma practice. We recently conducted a post hoc analysis of a randomized trial, in which treating physicians could choose whether to administer doxorubicin by continuous infusion or bolus. Cardiac adverse events were, not surprisingly, associated with cumulative doxorubicin dose, rather than mode of treatment administration. It is likely that limiting doxorubicin dosing, typically to 450 mg/m², obviates any benefit of continuous infusion in limiting doxorubicin cardiomyopathy.

A long-standing objective in sarcoma research has been the identification of companion agents for doxorubicin to enhance its activity. Doxorubicin plus ifosfamide has been under investigation since the 1990s. Earlier clinical trials of the combination were underpowered, gave limited doses of ifosfamide due to myelosuppression, and enrolled patients with chemotherapy-insensitive histologies. A trial conducted in Europe and published in 2014 definitively addressed the role of the doxorubicin/ifosfamide combination. Combined therapy with these two agents yields higher response rates and better PFS than doxorubicin alone, without an overall survival benefit. The combination is appropriate when achieving a response matters (for example, in the neoadjuvant setting to enable resection of marginally operable disease or if a response could provide significant palliation) but it carries substantially more toxicity and has not proven superior for overall survival.

Several other doxorubicin combinations have been explored in large phase III trials. These combinations include palifosfamide, evofosfamide, and olaratumab. All of these combinations with doxorubicin were first examined in the phase II setting, with promising results. The doxorubicin/olaratumab (anti-platelet-derived growth factor-beta antibody) combination even received contingent FDA approval due to a significant overall survival benefit in a randomized phase II study. In the phase III setting, all three combinations failed to meet their primary endpoints to demonstrate superiority to doxorubicin monotherapy.

With certain exceptions, doxorubicin monotherapy remains standard, first-line systemic therapy for advanced sarcoma treatment. Dexrazoxane as a cardioprotective agent, potentially from cycle 1, and white blood cell growth factor, due to risk of neutropenic fever, are adjunctive treatments in its administration.

Trabectedin Plus Doxorubicin in Leiomyosarcoma: A Landmark Result

A very important systemic therapy advance in sarcoma in recent years is the phase 3 trial of trabectedin plus doxorubicin in metastatic liposarcoma. Trabectedin, derived from a sea squirt (Ecteinascidia turbinata), has known activity in L-sarcomas (liposarcomas and leiomyosarcomas). A positive phase 2 trial led to this phase 3 study, in which patients were randomized to doxorubicin alone versus doxorubicin with trabectedin for six cycles, followed by trabectedin monotherapy maintenance for up to approximately 18 months.

The trial achieved statistical significance not only for progression-free survival, a relatively common result in this field, but for overall survival. The objective response rate was increased with the doxorubicin/trabectedin combination, a common finding in soft tissue sarcoma studies in which combination chemotherapy is administered. However, the overall survival benefit primarily became evident during the trabectedin monotherapy maintenance phase rather than the initial combination phase, suggesting that sustained trabectedin exposure drives the long-term benefit more than the initial combination. The improvement approximates a near-doubling of five-year survival, a landmark outcome for this histology.

This establishes a new standard of care for metastatic leiomyosarcoma and opens questions about perioperative use, applicability to other sarcoma subtypes (such as liposarcomas), use in patients with poor performance status, and integration into geriatric oncology frameworks.

Second-Line and Beyond: Gemcitabine-Based Regimens

Gemcitabine-based therapy plays an important role in second-line sarcoma management. The combinations of gemcitabine with docetaxel or dacarbazine have demonstrated overall survival benefits over monotherapy (with either gemcitabine or dacarbazine, respectively) in randomized trials. They are generally well tolerated as salvage therapy.

Gemcitabine-based regimens do not replace doxorubicin as first-line treatment. A randomized trial comparing gemcitabine-docetaxel therapy to doxorubicin in the first-line setting found no meaningful difference in outcomes. Adverse events in the trial actually favored doxorubicin, which is also simpler to administer. Doxorubicin remains the first-line standard.

Metastasectomy: Biology, Not Just Surgery

For patients who develop metastatic sarcoma, surgery remains relevant even in the setting of distant disease. A review of eight studies with over 1,000 patients confirmed five-year overall survival benefits from metastasectomy in carefully selected patients. The predictors of benefit were complete resection of all disease, fewer and smaller metastases, and a longer disease-free interval between the primary diagnosis and the development of metastatic disease. The latter two factors are noteworthy as biological variables that identify patients whose tumor biology is compatible with durable control through surgery, not simply patients who can technically undergo surgery. Metastasectomy is not appropriate for all patients with metastatic sarcoma, but it is an important tool when the biology and clinical setting support it.

For Patients

If you have been diagnosed with sarcoma, one of the most important things to know is that these tumors are not all the same. The specific type and grade of sarcoma you have matters enormously for treatment planning and prognosis. For some sarcoma subtypes, chemotherapy dramatically improves survival and should always be part of treatment. For others, surgery and radiation are the primary tools and chemotherapy’s benefit is more modest. Ask your oncologist whether your specific histology has been confirmed at a center with sarcoma pathology expertise, and whether you are being evaluated at or in consultation with a specialized sarcoma program. Clinical trials are particularly important in sarcoma given the rarity of individual histologies. The treatment of sarcomas is improving, bringing hope for better outcomes for patients facing these conditions in the future.

Key Takeaways

• Tumor grade is the single most important prognostic variable in sarcoma; staging and treatment must be histology- and anatomically specific.

• Surgery plus radiation achieves approximately excellent local control; metastatic disease developing in approximately 50% of patients remains the central challenge.

• Perioperative chemotherapy has proven level-1 survival benefit in Ewing’s sarcoma, osteosarcoma, and rhabdomyosarcoma; benefit in other soft tissue sarcomas is modest and should be guided by a careful discussion of risks and benefits.

• Neoadjuvant pembrolizumab concurrent with radiation improved disease-free survival in UPS, dedifferentiated liposarcoma, pleomorphic liposarcoma, and myxofibrosarcoma; now in NCCN guidelines for these histologies.

• Doxorubicin monotherapy remains a viable treatment option in advanced sarcomas.

• Dexrazoxane from cycle 1 may suppress doxorubicin-related cardiomyopathy and enable higher cumulative dosing in responsive patients.

• Trabectedin plus doxorubicin, with trabectedin maintenance, produced overall survival benefit in metastatic leiomyosarcoma in a randomized trial compared to doxorubicin monotherapy, a landmark achievement in this field; this represents a new standard of care for leiomyosarcoma.

• Metastasectomy may be an effective treatment option in selected patients with metastatic disease. The ability to undergo complete resection, a limited disease burden, and long disease-free interval prior to metastatic diagnosis are associated with survival benefit.

References

1. Pasquali S, et al. The impact of chemotherapy on survival of patients with extremity and trunk wall soft tissue sarcoma: revisiting the results of the EORTC-STBSG 62931 randomised trial. Eur J Cancer. 2019;109:51–60.

2. Sarculator nomogram. Available at https://www.sarculator.com.

3. Mowery Y, Ballman K, Hong A, et al. Safety and efficacy of pembrolizumab, radiation therapy, and surgery versus radiation therapy and surgery for stage III soft tissue sarcoma of the extremity (SU2C-SARC032). The Lancet. 2024;404:2053–2064.

4. Cranmer LD, Lu Y, Heise RS, et al. Bolus versus Continuous Intravenous Delivery of Doxorubicin in Soft-Tissue Sarcomas: Post Hoc Analysis of a Prospective Randomized Trial (SARC021/TH CR-406). Clin Cancer Res. 2023;29(6):1068–1076.

5. Maki RG, Wathen JK, Patel SR, et al. Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas. J Clin Oncol. 2007;25(19):2755–2763.

6. García-Del-Muro X, López-Pousa A, Maurel J, et al. Randomized phase II study comparing gemcitabine plus dacarbazine versus dacarbazine alone in patients with previously treated soft tissue sarcoma. J Clin Oncol. 2011;29(18):2528–2533.

7. Seddon B, Strauss S, Whelan J, et al. Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS). The Lancet Oncology. 2017;18:1397–1410.

8. Tawbi HA, Burgess M, Bolejack V, et al. Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028). Lancet Oncol. 2017;18(11):1493–1501.

9. Pautier P, Italiano A, Piperno-Neumann S, et al. Doxorubicin–Trabectedin with Trabectedin Maintenance in Leiomyosarcoma. N Engl J Med. 2024;391:789–799.

10. Stamenovic D, Hohenberger P, Roessner E. Pulmonary metastasectomy in soft tissue sarcomas: a systematic review. J Thorac Dis. 2021;13(4):2649–2660.

11. Cranmer L. “Sarcoma.” Presented at the 2026 Alaska Hematology Oncology Conference, Anchorage, AK, May 2026.

Related Reading on The Cancer News

Top 5 Takeaways from Dr. Paolo Tarantino on the Future of Antibody-Drug Conjugates in Solid Oncology

The Immunotherapy Landscape in Colorectal Cancer: Where We Stand and Where We’re Headed

The Hidden Barrier to Precision Oncology: How Insurance Policies Delay Access to Genomic Testing